Israel China Biotechnology (ICB) Ltd (ICB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) has a cash flow conversion efficiency ratio of -0.415x as of June 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.06 Million ≈ $-2.84K USD) by net assets (ILA2.55 Million ≈ $6.83K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ICB stock market capitalisation for the company's overall valuation and market capitalisation.
Israel China Biotechnology (ICB) Ltd - Cash Flow Conversion Efficiency Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Israel China Biotechnology (ICB) Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Israel China Biotechnology (ICB) Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of Israel China Biotechnology (ICB) Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pivotal Metals Ltd
AU:PVT
|
-0.038x |
|
Premium Catering (Holdings) Limited
NASDAQ:PC
|
N/A |
|
Jindo.Co. Ltd
KO:088790
|
0.016x |
|
Shah Alloys Limited
NSE:SHAHALLOYS
|
-0.149x |
|
Palatin Technologies, Inc. Common Stock
NASDAQ:PTN
|
-0.417x |
|
Tah Tong Textile Co Ltd
TW:1441
|
0.014x |
|
NEXTCHIP Co. Ltd
KQ:092600
|
-0.132x |
|
Octopus Robots SA
PA:MLOCT
|
N/A |
Annual Cash Flow Conversion Efficiency for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual cash flow conversion efficiency of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. View ICB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | ILA470.00K ≈ $1.26K |
ILA-4.34 Million ≈ $-11.63K |
-9.232x | -312.74% |
| 2019-12-31 | ILA1.89 Million ≈ $5.06K |
ILA-4.22 Million ≈ $-11.32K |
-2.237x | -248.93% |
| 2018-12-31 | ILA7.41 Million ≈ $19.87K |
ILA-4.75 Million ≈ $-12.74K |
-0.641x | -134.10% |
| 2017-12-31 | ILA-1.69 Million ≈ $-4.52K |
ILA-3.17 Million ≈ $-8.50K |
1.880x | +190.81% |
| 2016-12-31 | ILA1.91 Million ≈ $5.11K |
ILA-3.94 Million ≈ $-10.58K |
-2.070x | -213.83% |
| 2015-12-31 | ILA5.78 Million ≈ $15.50K |
ILA-3.81 Million ≈ $-10.23K |
-0.660x | -- |
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.